Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events

Ibrutinib is an oral inhibitor of Bruton ’s tyrosine kinase (BTK) that is FDA-approved for several lymphoproliferative disorders and chronic GVHD.

Source: Journal of the American Academy of Dermatology - December 19, 2019 Category: Dermatology Authors: Sean Singer, Sally Y. Tan, Anna K. Dewan, Matthew Davids, Ann S. LaCasce, Steven P. Treon, Nicole R. LeBoeuf Source Type: research